131,910$
-0,01%
Echtzeit-Aktienkurs Intra-Cellular Therapies Inc.
Bid:
Ask:
Echtzeit-Chart der Intra-Cellular Therapies Inc. Aktie
Börsenkurse Intra-Cellular Therapies Inc.
| Echtzeit Euro | - | - | - | - | 122,500€ | 0,41% |
| gettex | - | - | - | - | 122,500€ | 0,82% |
| USA | - | - | - | - | 131,870$ | -0,05% |
| Lang & Schwarz | - | - | - | - | 122,500€ | 0,00% |
| Nasdaq | - | - | - | - | 131,910$ | -0,01% |
| Echtzeit USD | - | - | - | - | 132,264$ | 0,25% |
| Börse Frankfurt | - | - | - | - | - | - |
| Börse Stuttgart | - | - | - | - | 122,000€ | 0,83% |
| Tradegate | - | - | - | - | 122,000€ | -0,81% |
Fundamentaldaten der Intra-Cellular Therapies Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2024 [USD] | 680,85 Mio. | -74,20 Mio. | -74,68 Mio. | -0,72 | - | - | 20,58 |
| 2023 [USD] | 464,37 Mio. | -139,04 Mio. | -139,67 Mio. | -1,46 | - | - | 27,38 |
| 2022 [USD] | 250,31 Mio. | -256,25 Mio. | -256,26 Mio. | -2,73 | - | - | 49,97 |
| 2021 [USD] | 83,80 Mio. | -284,12 Mio. | -284,13 Mio. | -3,50 | - | - | 128,89 |
| 2020 [USD] | 22,81 Mio. | -226,99 Mio. | -227,01 Mio. | -3,23 | - | - | 465,26 |
| 2019 [USD] | 0,06 Mio. | -147,72 Mio. | -147,72 Mio. | -2,68 | - | - | 120799,07 |
| 2018 [USD] | - | -155,13 Mio. | -155,13 Mio. | -2,84 | - | - | - |
| 2017 [USD] | 0,25 Mio. | -98,83 Mio. | -97,77 Mio. | -2,12 | - | - | 29295,75 |
| 2016 [USD] | 0,33 Mio. | -115,36 Mio. | -116,43 Mio. | -2,69 | - | - | 17268,62 |
| 2015 [USD] | 0,09 Mio. | -104,79 Mio. | -104,79 Mio. | -2,91 | - | - | 62307,82 |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Intra-Cellular Therapies Inc. Aktie
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.